Skip to content

Study · Randomized controlled trial · n = 14 · 2014

2 results

Oxytocin nasal spray in fibromyalgic patients.

Mameli S, Pisanu GM, Sardo S, Marchi A, Pili A, Carboni M, Minerba L, Trincas G, Carta MG, Melis MR, Agabio R

Rheumatology international8 Feb 2014Cited by 43 (Europe PMC)

PMID24509894 (opens in a new tab)DOI10.1007/s00296-014-2953-y (opens in a new tab)PepBankPUB-24509894
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with fibromyalgia, intranasal oxytocin 80 IU a day did not induce positive therapeutic effects compared with placebo.

    In plain wordsIn women with fibromyalgia, oxytocin nasal spray did not give benefit compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeTherapeutic effects in fibromyalgia
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    80 IU a day · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Unlikely, oxytocin nasal spray (80 IU a day) did not induce positive therapeutic effects
    1 context sentence
    Summary · context
    To evaluate this hypothesis, 14 women affected by fibromyalgia and comorbid disorders, assuming a complex pharmacotherapy, were enrolled in a double-blind, crossover, randomized trial to receive oxytocin and placebo nasal spray daily for 3 weeks for each treatment.
  2. 02HumanRandomized controlled trialSafety outcome

    In women with fibromyalgia, intranasal oxytocin 80 IU a day was reported as safe and devoid of toxicity.

    In plain wordsIn women with fibromyalgia, oxytocin nasal spray was reported as safe, with no toxicity.

    Peptide
    Oxytocin
    Outcome
    No significant changeSafety and toxicity
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    80 IU a day · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    but resulted to be safe, devoid of toxicity
    1 context sentence
    Summary · context
    To evaluate this hypothesis, 14 women affected by fibromyalgia and comorbid disorders, assuming a complex pharmacotherapy, were enrolled in a double-blind, crossover, randomized trial to receive oxytocin and placebo nasal spray daily for 3 weeks for each treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.